PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)
Solid Tumor|Unresectable or Metastatic Melanoma
DRUG: CX-072|DRUG: Ipilimumab
Overall Response Rate by RECIST v 1.1, ORR by RECIST v1.1, 1 year
The Percentage of Patients Experiencing Treatment Related Adverse Events, Safety and Tolerability of CX-072 in Combination Therapy, 2 years|The Numbers of Patients Experiencing Anti-tumor Activity by irRECIST, ORR by irRECIST, 2 years
To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)